Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) — Capital Reinvestment Ratio

Latest as of March 2026: 0.13x

Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has a Capital Reinvestment Ratio of 0.13x as of March 2026, meaning it reinvests 0% of its operating cash flow (TL180.45 Million) in capital expenditures (TL24.08 Million). See Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.13x
Capex / Operating Cash Flow

Operating Cash Flow

TL180.45 Million
TRY

Capital Expenditures

TL24.08 Million
TRY

Data as of

Mar 2026
Most recent filing

Meditera Tibbi Malzeme Sanayi ve Ticaret AS Capital Reinvestment Ratio (2020–2025)

This chart tracks Meditera Tibbi Malzeme Sanayi ve Ticaret AS's Capital Reinvestment Ratio across 6 annual periods.

Annual Capital Reinvestment Ratio for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2020–2025)

Year-by-year Capital Reinvestment Ratio for Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2020 to 2025. For live market cap and broader valuation context, see how much is Meditera Tibbi Malzeme Sanayi ve Ticaret worth.

Year Reinvestment Ratio Operating CF (TRY) Capital Expenditures YoY Change
2025 0.44x TL435.35 Million TL191.67 Million ▲ +30.4%
2024 0.34x TL780.69 Million TL263.52 Million ▼ -9.8%
2023 0.37x TL801.02 Million TL299.70 Million ▼ -96.3%
2022 10.07x TL5.10 Million TL51.35 Million ▲ +4036.4%
2021 0.24x TL36.64 Million TL8.92 Million ▼ -14.5%
2020 0.28x TL73.26 Million TL20.85 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow